Marieke van Son

58 CHAPTER 3 15. van der Wielen GJ, Mulhall JP, Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiother Oncol 2007 Aug;84(2):107-113. 16. Lee JY, Spratt DE, Liss AL, McLaugh- lin PW. Vessel-sparing radiation and functional anatomy-based preserva- tion for erectile function after pros- tate radiotherapy. Lancet Oncol 2016 May;17(5):e198-208. 17. Cosset JM, Cathelineau X, Wakil G, Pierrat N, Quenzer O, Prapotnich D, et al. Focal brachytherapy for se- lected low-risk prostate cancers: a pilot study. Brachytherapy 2013 Jul- Aug;12(4):331-337. 18. Graff P, Portalez D, Lusque A, Brun T, Aziza R, Khalifa J, et al. IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2018 Nov 15;102(4):903-911. 19. Barret E, Ahallal Y, Sanchez-Salas R, Ga- liano M, Cosset JM, Validire P, et al. Mor- bidity of focal therapy in the treatment of localized prostate cancer. Eur Urol. 2013 Apr;63(4):618-22. 20. Tselis N, Hoskin P, Baltas D, Strnad V, Zamboglou N, Rodel C, et al. High Dose Rate Brachytherapy as Monotherapy for Localised Prostate Cancer: Review of the Current Status. Clin Oncol (R Coll Radiol) 2017 Jul;29(7):401-411. 21. Morton G, Chung HT, McGuffin M, Helou J, D’Alimonte L, Ravi A, et al. Pros- tate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy. Radio- ther Oncol 2017 Jan;122(1):87-92. 22. Prada PJ, Cardenal J, Blanco AG, An- chuelo J, Ferri M, Fernandez G, et al. High-dose-rate interstitial brachyther- apy as monotherapy in one fraction for the treatment of favorable stage pros- tate cancer: Toxicity and long-term bio- chemical results. Radiother Oncol 2016 Jun;119(3):411-416. 23. Prada PJ, Ferri M, Cardenal J, Blanco AG, Anchuelo J, Diaz de Cerio I, et al. High- dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemi- cal results. Brachytherapy 2018 Nov - Dec;17(6):845-851. 24. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensi- tivity of prostate cancer deduced from radiotherapy outcomes of 5,969 pa- tients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012 Jan 1;82(1):e17-24. 25. KasivisvanathanV, RannikkoAS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 2018 May 10;378(19):1767-1777. 26. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013 May;111(5):753-60. 27. Loeb S, Folkvaljon Y, Robinson D, Liss- brant IF, Egevad L, Stattin P. Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort. Eur Urol. 2016 Jun;69(6):1135-41. 28. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Pros- tate Cancer. Part 1: Screening, Diagno- sis, and Local Treatment with Curative Intent. Eur Urol 2017 Apr;71(4):618-629.